Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing–remitting multiple sclerosis is effective and safe
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Neurology"
DOI: 10.1007/s00415-019-09195-2
Abstract: BackgroundIt has been described that treating relapsing–remitting multiple sclerosis (RRMS) patients with alemtuzumab following fingolimod could be less effective due to the different dynamics of lymphocyte repopulation. Effectiveness and safety of alemtuzumab compared to rituximab… read more here.
Keywords: rituximab fingolimod; alemtuzumab rituximab; fingolimod withdrawal; fingolimod ... See more keywords